<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">TAMARI, KEISUKE</style></author><author><style face="normal" font="default" size="100%">ISOHASHI, FUMIAKI</style></author><author><style face="normal" font="default" size="100%">AKINO, YUICHI</style></author><author><style face="normal" font="default" size="100%">SUZUKI, OSAMU</style></author><author><style face="normal" font="default" size="100%">SEO, YUJI</style></author><author><style face="normal" font="default" size="100%">YOSHIOKA, YASUO</style></author><author><style face="normal" font="default" size="100%">HAYASHI, YOSHITO</style></author><author><style face="normal" font="default" size="100%">NISHIDA, TSUTOMU</style></author><author><style face="normal" font="default" size="100%">TAKEHARA, TETSUO</style></author><author><style face="normal" font="default" size="100%">MORI, MASAKI</style></author><author><style face="normal" font="default" size="100%">DOKI, YUICHIRO</style></author><author><style face="normal" font="default" size="100%">OGAWA, KAZUHIKO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk Factors for Pericardial Effusion in Patients with Stage I Esophageal Cancer Treated with Chemoradiotherapy</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">7389-7393</style></pages><volume><style face="normal" font="default" size="100%">34</style></volume><issue><style face="normal" font="default" size="100%">12</style></issue><abstract><style  face="normal" font="default" size="100%">Aim: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy. Patients and Methods: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed. Results: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥41.6%, age ≥66 years, body mass index (BMI) ≥19 and diabetes mellitus (DM) were significant predictors of developing PCE. Conclusion: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.</style></abstract></record></records></xml>